Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

Authors: Le, Xiuning, Cornelissen, Robin, Garassino, Marina, Clarke, Jeffrey M., Tchekmedyian, Nishan, Goldman, Jonathan W., Leu, Szu-Yun, Bhat, Gajanan, Lebel, Francois, Heymach, John V., Socinski, Mark A.

Source: Journal of clinical oncology. 40(7):710-718

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100148750694.0x000001&indx=1&recIds=ETOCvdc_100148750694.0x000001

An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC

Authors: Zhu, Viola W., Lin, Yen-Ting, Kim, Dong-Wan, Loong, Herbert H., Nagasaka, Misako, To, Hao, Ang, Yvonne Li-En, Ock, Chan-Young, Tchekmedyian, Nishan, Ou, Sai-Hong Ignatius, Syn, Nicholas L., Reungwetwattana, Thanyanan, Lin, Chia-Chi, Soo, Ross A.

Source: In Journal of Thoracic Oncology September 2020 15(9):1484-1496

Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series

Authors: Tchekmedyian, Nishan, Mudad, Raja, Blanco, Fernando F., Raymond, Victoria M., Garst, Jordan, Erlander, Mark G., Haura, Eric, Berz, David

Source: Lung cancer. 108:22-28

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100084288828.0x000001&indx=1&recIds=ETOCvdc_100084288828.0x000001

Propelling Immunotherapy Combinations Into the Clinic

Authors: Tchekmedyian, Nishan, Gray, Jhanelle E., Creelan, Benjamin C., Chiappori, Alberto A., Beg, Amer A., Soliman, Hatem, Perez, Bradford A., Antonia, Scott J.

Source: Oncology. 29(12):990-1004

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN604483784&indx=1&recIds=ETOCRN604483784

CNS activity of poziotinib in NSCLC with exon 20 insertion mutations.

Authors: Le, Xiuning, Garassino, Marina Chiara, Cornelissen, Robin, Socinski, Mark A., Tchekmedyian, Nishan, Molina, Julian R., Baik, Christina S, Leu, Sharon, Dreiling, Lyndah, Lebel, Francois M., Clarke, Jeffrey Melson

Source: Journal of clinical oncology. 39(15 suppl):9093-9093

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173220155.0x000001&indx=1&recIds=ETOCvdc_100173220155.0x000001

Poziotinib in Non-Small-Cell Lung Cancer Harboring Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.

Authors: Le, Xiuning, Cornelissen, Robin, Garassino, Marina, Clarke, Jeffrey M, Tchekmedyian, Nishan, Goldman, Jonathan W, Leu, Szu-Yun, Bhat, Gajanan, Lebel, Francois, Heymach, John V, Socinski, Mark A

Source: Journal of Clinical Oncology; 3/1/2022, Vol. 40 Issue 7, p710-718, 9p

Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib

Authors: Tchekmedyian, Nishan, Ali, Siraj M., Miller, Vincent A., Haura, Eric B.

Source: Journal of thoracic oncology. 11(7):e87-e88

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100041018071.0x000001&indx=1&recIds=ETOCvdc_100041018071.0x000001

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia after Same-Day Dosing of Eflapegrastim in Patients with Breast Cancer Receiving Docetaxel and Cyclophosphamide (NCT04187898)

Authors: Schwartzberg, Lee S., Francis, Jawad ^*, Osama, Hlalah ^*, Modiano, Manuel ^*, Bharadwaj, Jayaram ^*, Chawla, Shanta ^*, Bhat, Gajanan ^*, Lebel, Francois ^*, Tchekmedyian, Nishan ^*

Source: In Blood 5 November 2020 136 Supplement 1:34-35

Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib

Authors: Tchekmedyian, Nishan, Paxton, Bill, Lebel, Francois, Keossayan, Lena, Heymach, John V.

Source: In JTO Clinical and Research Reports November 2020 1(4)

Plasma Cell Dyscrasias of the Lung: An Atypical Presentation of Non-IgM Lymphoplasmacytic Lymphoma

Authors: Wang, Emilie, Martin, Angel, Tchekmedyian, Nishan, Prithviraj, Gopi

Source: Chest. 150(4):1098A-1098A

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100049342525.0x000001&indx=1&recIds=ETOCvdc_100049342525.0x000001

P3.02b-012 Longitudinal Monitoring of ctDNA EGFR Mutation Burden from Urine Correlates with Patient Response to EGFR TKIs: A Case Series: Topic: EGFR Biomarkers

Authors: Tchekmedyian, Nishan, Mudad, Raja, Haura, Eric, Blanco, Fernando, Raymond, Victoria, Erlander, Mark, Garst, Jordan, Berz, David

Source: In Journal of Thoracic Oncology January 2017 12(1) Supplement:S1192-S1193

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Prolonged Central Nervous System Response in a Patient With HER2Mutant NSCLC Treated With First-Line Poziotinib

Authors: Tchekmedyian, Nishan, Paxton, Bill, Lebel, Francois, Keossayan, Lena, Heymach, John V.

Source: JTO Clinical and Research Reports; November 2020, Vol. 1 Issue: 4

This result is not displayed to guests.
Login for full access.

Acquired ALKL1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib

Authors: Tchekmedyian, Nishan, Ali, Siraj M., Miller, Vincent A., Haura, Eric B.

Source: Journal of Thoracic Oncology; July 2016, Vol. 11 Issue: 7 pe87-e88, 2p

This result is not displayed to guests.
Login for full access.